Psoriasis clinical trials at UCSF

7 in progress, 5 open to eligible people

Psoriasis is a skin condition that causes red, scaly patches. UCSF is studying the immune response in psoriasis using treatments like deucravacitinib and guselkumab. Another trial looks at how sleep affects people with moderate to severe psoriasis. The impact of tildrakizumab on immune cells is also under investigation.

Showing trials for

  • Correction of Psoriatic T Cell Signatures by Deucravacitinib

    open to eligible people ages 18-75

    This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

    San Francisco, California

  • Guselkumab Immunogenetics

    open to eligible people ages 18 years and up

    This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.

    San Francisco, California

  • Immune Spatial Features of Guselkumab Cutaneous Response

    open to eligible people ages 18 years and up

    This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.

    San Francisco, California

  • Psoriatic Immune Response to Tildrakizumab

    open to eligible people ages 18-75

    This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

    San Francisco, California

  • Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

    open to eligible people ages 18 years and up

    Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.

    San Francisco, California

  • JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

    Sorry, in progress, not accepting new patients

    The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

    Fresno, California and other locations

  • Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.

    Fresno, California and other locations

Our lead scientists for Psoriasis research studies include .

Last updated: